Table 5.

Analysis of risk factors for the primary outcome measure (aggregate incidence of pancreatic fistula/leak/abscess) amongst patients in the study arm alone (received pasireotide, N = 652) via univariable logistic regression. A full dose of pasireotide is considered 14 total doses given twice daily or continued administration until discharge, whichever occurs earlier. C.I., confidence interval.

Characteristic	Incidence/Number at Risk (%)	Odds Ratio	95% C.I.	p-value
Received Full Course (14 Doses)
Yes	77/544 (14.2)	1.62	[0.81 – 3.23]	0.18
No	10/108 (9.3)
Incremental Days on Pasireotide	87/652 (13.3)	1.07	[0.86 – 1.32]	0.55
Gland Texture
Soft	63/392 (16.1)	1.87	[1.14 – 3.09]	0.014
Firm	24/259 (9.3)	Ref.
Duct Size
> 4 mm	29/282 (10.3)	0.61	[0.38 – 0.99]	0.044
≤ 4 mm	58/368 (15.8)	Ref.
Risk Profile
High (≤4 mm and soft)	49/308 (15.9)	2.31	[1.26 – 4.24]
Moderate (≤4 mm or soft)	23/144 (16.0)	2.32	[1.16 – 4.62]	0.019
Low (>4 mm duct, firm)	15/198 (7.6)	Ref.